Article Figures & Data
Figures
- FIGURE 1.
Images of patient 1 showing localization of metastases (solid arrows), kidney (dotted arrows), and liver (dashed arrows). γ-camera imaging was performed after intravenous injection of 123 MBq of 111In-ABY-002 with peptide mass dose of less than 100 μg. Whole-body scan 4 h after injection (left) shows uptake predominantly in liver and kidney, with additional uptake in parotid and submandibular glands, thorax, and gastrointestinal tract. SPECT images 3 h after injection (middle) show the localization of thoracic wall metastasis (upper coronal image and sagittal image) and mediastinal lymph node metastases (lower coronal image). Findings indicate HER2-positive metastases in mediastinal lymph nodes and thoracic wall, as was confirmed for the thoracic wall metastasis by HercepTest score of 3+. PET was performed after intravenous injection of 293 MBq of 18F-FDG. Coronal maximum-intensity-projection image 90 min after injection (right) shows localization of thoracic wall metastasis and mediastinal lymph node metastases.
- FIGURE 2.
Images of patient 3 obtained 85 min after intravenous injection of 278 MBq of 18F-FDG and 135 min after intravenous injection of 267 MBq of 68Ga-ABY-002 with peptide mass dose of less than 100 μg. (A) Potential metastasis (arrows) in chest wall near the axilla is seen with 68Ga-ABY-002 on transverse PET (top), CT (middle), and PET/CT (bottom) images and on coronal maximum-intensity-projection images (in between). This metastasis was not visible with 18F-FDG. (B) 18F-FDG (left column) and 68Ga-ABY-002 (right column) transverse images of identified lesions (arrows) in pelvic area.
- FIGURE 3.
Blood kinetics in the 3 patients. Samples were collected at predetermined times after injection of radiolabeled ABY-002; radioactivity was measured with γ-counter (Isomed 2000; Nuklear Medizintechnik Dresden) and plotted over time; and values were applied for kinetic analysis using Origin Pro 7G (OriginLab) and exponential curve fit function ExpDec 1/2. (A) Blood kinetics of 111In-ABY-002 in patients 1 (administered dose, 123 MBq [▴]) and 3 (101.3 MBq [•]). Time points between 22 and 94 h after injection are not included. (B) Blood kinetics of 68Ga-ABY-002 in patients 1 (110 MBq [▴]), 2 (187 MBq [
]), and 3 (267 MBq [•]).
Tables
Patient Characteristic 1 2 3 Age at imaging (y) 64 39 58 TNM classification pT2 pN1 Mx pT1c pN1a(2/11) M0, L0, V0, R0 pT2 pN0 M0 Grade G2–3 G3 G2 Receptor status at diagnosis ER/PR-positive ER/PR-negative ER/PR-negative Tumor marker Ki-67, 20% HER2 status at diagnosis Not analyzed 3+ 3+ Trastuzumab treatment Not before ABY-002 imaging Not before ABY-002 imaging Ongoing at time of ABY-002 imaging 18F-FDG PET/CT Day 0 Day 0 Day 0 Dose 293 MBq 284 MBq 278 MBq Whole-body PET/CT 90 min after injection 95 min after injection 85 min after injection 111In-ABY-002 Day 35 Day 13 Dose 123 MBq 101.3 MBq Dynamic scan 1–30 min WBS 1, 2, 4, and 72 h after injection 2, 4, and 20 h after injection SPECT 3 h after injection 20 h after injection 68Ga-ABY-002 Day 74 Day 19 Day 14 Dose 110 MBq 187 MBq 267 MBq Whole-body PET/CT 90 and 250 min after injection 95 min after injection 135 min after injection ER/PR = estrogen receptor/progesterone receptor.
Last 18F-FDG PET/CT scan was set as day 0.
Patient 2 Patient 3 Site 18F-FDG 68Ga-ABY-002 18F-FDG 68Ga-ABY-002 Region of liver metastasis 9.0 18.2 (surrounding normal liver, 15.6–18.2) Left iliac spine 8.6 2.5 Soft tissue close to iliac bone 8.6 4.3 Acetabulum/femur head 8.6 2.1 Sartorius muscle 3.7 2.4 Potential lymphangiosis within quadriceps muscle 4.8 2.6 Potential chest wall lesion 1.6
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging
- In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET
- Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
- Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial
- Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside
- Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2
- Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma
- Targeting diverse protein-protein interaction interfaces with {alpha}/{beta}-peptides derived from the Z-domain scaffold
- An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein
- 188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment
- First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
- Novel Ubiquitin-derived High Affinity Binding Proteins with Tumor Targeting Properties
- Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies
- Imaging of Platelet-Derived Growth Factor Receptor {beta} Expression in Glioblastoma Xenografts Using Affibody Molecule 111In-DOTA-Z09591
- Three Methods for 18F Labeling of the HER2-Binding Affibody Molecule ZHER2:2891 Including Preclinical Assessment
- Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein
- Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer
- HER2-Positive Tumors Imaged Within 1 Hour Using a Site-Specifically 11C-Labeled Sel-Tagged Affibody Molecule
- PET of EGFR Expression with an 18F-Labeled Affibody Molecule
- Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site Composition
- Optical Imaging with Her2-Targeted Affibody Molecules Can Monitor Hsp90 Treatment Response in a Breast Cancer Xenograft Mouse Model
- Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule 111In-DOTA-ZIGF1R:4551
- Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with 18F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer
- Immuno-PET of Cancer: A Revival of Antibody Imaging
- Optimization of Hapten-Peptide Labeling for Pretargeted ImmunoPET of Bispecific Antibody Using Generator-Produced 68Ga
- Molecular Design and Optimization of 99mTc-Labeled Recombinant Affibody Molecules Improves Their Biodistribution and Imaging Properties
- Structural basis for high-affinity HER2 receptor binding by an engineered protein
- Targeting of HER2-Expressing Tumors Using 111In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold